nodes	percent_of_prediction	percent_of_DWPC	metapath
Desvenlafaxine—CYP3A4—prostate cancer	0.283	1	CbGaD
Desvenlafaxine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0877	0.207	CbGbCtD
Desvenlafaxine—CYP3A4—Bicalutamide—prostate cancer	0.0461	0.109	CbGbCtD
Desvenlafaxine—CYP3A4—Estramustine—prostate cancer	0.0428	0.101	CbGbCtD
Desvenlafaxine—CYP3A4—Abiraterone—prostate cancer	0.0382	0.09	CbGbCtD
Desvenlafaxine—CYP3A4—Flutamide—prostate cancer	0.0382	0.09	CbGbCtD
Desvenlafaxine—CYP3A4—Cabazitaxel—prostate cancer	0.0282	0.0666	CbGbCtD
Desvenlafaxine—CYP3A4—Estrone—prostate cancer	0.0276	0.0651	CbGbCtD
Desvenlafaxine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0246	0.058	CbGbCtD
Desvenlafaxine—CYP3A4—Conjugated Estrogens—prostate cancer	0.0181	0.0426	CbGbCtD
Desvenlafaxine—CYP3A4—Mitoxantrone—prostate cancer	0.0164	0.0387	CbGbCtD
Desvenlafaxine—CYP3A4—Estradiol—prostate cancer	0.0159	0.0374	CbGbCtD
Desvenlafaxine—CYP3A4—Prednisone—prostate cancer	0.0136	0.0321	CbGbCtD
Desvenlafaxine—CYP3A4—Etoposide—prostate cancer	0.0104	0.0244	CbGbCtD
Desvenlafaxine—CYP3A4—Docetaxel—prostate cancer	0.00947	0.0223	CbGbCtD
Desvenlafaxine—CYP3A4—Doxorubicin—prostate cancer	0.00706	0.0166	CbGbCtD
Desvenlafaxine—Venlafaxine—CYP2C19—prostate cancer	0.000827	0.611	CrCbGaD
Desvenlafaxine—Venlafaxine—CYP3A4—prostate cancer	0.000526	0.389	CrCbGaD
Desvenlafaxine—Malnutrition—Docetaxel—prostate cancer	0.000125	0.000522	CcSEcCtD
Desvenlafaxine—Rash—Conjugated Estrogens—prostate cancer	0.000125	0.000521	CcSEcCtD
Desvenlafaxine—Chills—Capecitabine—prostate cancer	0.000125	0.000521	CcSEcCtD
Desvenlafaxine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000125	0.000521	CcSEcCtD
Desvenlafaxine—Headache—Conjugated Estrogens—prostate cancer	0.000124	0.000518	CcSEcCtD
Desvenlafaxine—Hallucination—Prednisone—prostate cancer	0.000123	0.000515	CcSEcCtD
Desvenlafaxine—Alopecia—Capecitabine—prostate cancer	0.000123	0.000513	CcSEcCtD
Desvenlafaxine—Dysgeusia—Docetaxel—prostate cancer	0.000123	0.000511	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—TH—prostate cancer	0.000122	0.00237	CbGpPWpGaD
Desvenlafaxine—Mental disorder—Capecitabine—prostate cancer	0.000122	0.000509	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Prednisone—prostate cancer	0.000122	0.000508	CcSEcCtD
Desvenlafaxine—Malnutrition—Capecitabine—prostate cancer	0.000121	0.000506	CcSEcCtD
Desvenlafaxine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	0.000121	0.00235	CbGpPWpGaD
Desvenlafaxine—Tachycardia—Etoposide—prostate cancer	0.00012	0.000501	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Doxorubicin—prostate cancer	0.00012	0.0005	CcSEcCtD
Desvenlafaxine—SLC6A2—NRF2 pathway—RXRA—prostate cancer	0.00012	0.00233	CbGpPWpGaD
Desvenlafaxine—Skin disorder—Etoposide—prostate cancer	0.000119	0.000498	CcSEcCtD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000119	0.00231	CbGpPWpGaD
Desvenlafaxine—Nausea—Goserelin—prostate cancer	0.000119	0.000496	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Etoposide—prostate cancer	0.000119	0.000496	CcSEcCtD
Desvenlafaxine—Dysgeusia—Capecitabine—prostate cancer	0.000119	0.000495	CcSEcCtD
Desvenlafaxine—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000118	0.000494	CcSEcCtD
Desvenlafaxine—Nausea—Conjugated Estrogens—prostate cancer	0.000118	0.000491	CcSEcCtD
Desvenlafaxine—Breast disorder—Doxorubicin—prostate cancer	0.000117	0.000489	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Estradiol—prostate cancer	0.000117	0.000488	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000117	0.000487	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	0.000116	0.00226	CbGpPWpGaD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—IL10—prostate cancer	0.000116	0.00226	CbGpPWpGaD
Desvenlafaxine—Eye disorder—Prednisone—prostate cancer	0.000116	0.000484	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—EGR1—prostate cancer	0.000115	0.00224	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.000115	0.00223	CbGpPWpGaD
Desvenlafaxine—SLC6A2—NRF2 pathway—TGFBR2—prostate cancer	0.000115	0.00223	CbGpPWpGaD
Desvenlafaxine—SLC6A2—NRF2 pathway—GSTP1—prostate cancer	0.000115	0.00223	CbGpPWpGaD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—NGFR—prostate cancer	0.000114	0.00222	CbGpPWpGaD
Desvenlafaxine—Vision blurred—Capecitabine—prostate cancer	0.000114	0.000477	CcSEcCtD
Desvenlafaxine—Asthenia—Estradiol—prostate cancer	0.000114	0.000475	CcSEcCtD
Desvenlafaxine—Tremor—Capecitabine—prostate cancer	0.000114	0.000474	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	0.000113	0.0022	CbGpPWpGaD
Desvenlafaxine—Angiopathy—Prednisone—prostate cancer	0.000112	0.000469	CcSEcCtD
Desvenlafaxine—Syncope—Docetaxel—prostate cancer	0.000112	0.000468	CcSEcCtD
Desvenlafaxine—Immune system disorder—Prednisone—prostate cancer	0.000112	0.000467	CcSEcCtD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	0.000112	0.00217	CbGpPWpGaD
Desvenlafaxine—Palpitations—Docetaxel—prostate cancer	0.000111	0.000462	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Epirubicin—prostate cancer	0.000111	0.000461	CcSEcCtD
Desvenlafaxine—Paraesthesia—Etoposide—prostate cancer	0.00011	0.000461	CcSEcCtD
Desvenlafaxine—Weight increased—Epirubicin—prostate cancer	0.00011	0.00046	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Docetaxel—prostate cancer	0.00011	0.000459	CcSEcCtD
Desvenlafaxine—Weight decreased—Epirubicin—prostate cancer	0.00011	0.000457	CcSEcCtD
Desvenlafaxine—Alopecia—Prednisone—prostate cancer	0.00011	0.000457	CcSEcCtD
Desvenlafaxine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000109	0.00213	CbGpPWpGaD
Desvenlafaxine—Somnolence—Etoposide—prostate cancer	0.000109	0.000456	CcSEcCtD
Desvenlafaxine—Vertigo—Capecitabine—prostate cancer	0.000109	0.000454	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000109	0.000454	CcSEcCtD
Desvenlafaxine—Syncope—Capecitabine—prostate cancer	0.000109	0.000453	CcSEcCtD
Desvenlafaxine—Mental disorder—Prednisone—prostate cancer	0.000109	0.000453	CcSEcCtD
Desvenlafaxine—Diarrhoea—Estradiol—prostate cancer	0.000109	0.000453	CcSEcCtD
Desvenlafaxine—Convulsion—Docetaxel—prostate cancer	0.000108	0.000453	CcSEcCtD
Desvenlafaxine—Hypertension—Docetaxel—prostate cancer	0.000108	0.000451	CcSEcCtD
Desvenlafaxine—Malnutrition—Prednisone—prostate cancer	0.000108	0.00045	CcSEcCtD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.000108	0.00209	CbGpPWpGaD
Desvenlafaxine—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000107	0.000447	CcSEcCtD
Desvenlafaxine—Palpitations—Capecitabine—prostate cancer	0.000107	0.000447	CcSEcCtD
Desvenlafaxine—Decreased appetite—Etoposide—prostate cancer	0.000107	0.000446	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Capecitabine—prostate cancer	0.000107	0.000444	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000106	0.000443	CcSEcCtD
Desvenlafaxine—Asthenia—Mitoxantrone—prostate cancer	0.000106	0.000442	CcSEcCtD
Desvenlafaxine—Fatigue—Etoposide—prostate cancer	0.000106	0.000442	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000106	0.000442	CcSEcCtD
Desvenlafaxine—SLC6A2—NRF2 pathway—GSTM1—prostate cancer	0.000105	0.00205	CbGpPWpGaD
Desvenlafaxine—Constipation—Etoposide—prostate cancer	0.000105	0.000439	CcSEcCtD
Desvenlafaxine—Dizziness—Estradiol—prostate cancer	0.000105	0.000438	CcSEcCtD
Desvenlafaxine—Hypertension—Capecitabine—prostate cancer	0.000105	0.000437	CcSEcCtD
Desvenlafaxine—Dry mouth—Docetaxel—prostate cancer	0.000104	0.000435	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	0.000104	0.00202	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	0.000104	0.00202	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	0.000103	0.002	CbGpPWpGaD
Desvenlafaxine—Anxiety—Capecitabine—prostate cancer	0.000103	0.000429	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	0.000103	0.00199	CbGpPWpGaD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000102	0.000428	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Doxorubicin—prostate cancer	0.000102	0.000427	CcSEcCtD
Desvenlafaxine—Weight increased—Doxorubicin—prostate cancer	0.000102	0.000426	CcSEcCtD
Desvenlafaxine—Epistaxis—Epirubicin—prostate cancer	0.000102	0.000425	CcSEcCtD
Desvenlafaxine—Vision blurred—Prednisone—prostate cancer	0.000102	0.000424	CcSEcCtD
Desvenlafaxine—Weight decreased—Doxorubicin—prostate cancer	0.000101	0.000423	CcSEcCtD
Desvenlafaxine—Diarrhoea—Mitoxantrone—prostate cancer	0.000101	0.000422	CcSEcCtD
Desvenlafaxine—Dry mouth—Capecitabine—prostate cancer	0.000101	0.000421	CcSEcCtD
Desvenlafaxine—Vomiting—Estradiol—prostate cancer	0.000101	0.000421	CcSEcCtD
Desvenlafaxine—Shock—Docetaxel—prostate cancer	0.0001	0.000419	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Docetaxel—prostate cancer	0.0001	0.000418	CcSEcCtD
Desvenlafaxine—Rash—Estradiol—prostate cancer	0.0001	0.000417	CcSEcCtD
Desvenlafaxine—Dermatitis—Estradiol—prostate cancer	9.99e-05	0.000417	CcSEcCtD
Desvenlafaxine—Tachycardia—Docetaxel—prostate cancer	9.97e-05	0.000416	CcSEcCtD
Desvenlafaxine—Headache—Estradiol—prostate cancer	9.93e-05	0.000415	CcSEcCtD
Desvenlafaxine—Skin disorder—Docetaxel—prostate cancer	9.92e-05	0.000414	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	9.91e-05	0.000414	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—SIRT1—prostate cancer	9.9e-05	0.00192	CbGpPWpGaD
Desvenlafaxine—Angioedema—Prednisone—prostate cancer	9.86e-05	0.000412	CcSEcCtD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—HIF1A—prostate cancer	9.8e-05	0.0019	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTM3—prostate cancer	9.78e-05	0.0019	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	9.78e-05	0.0019	CbGpPWpGaD
Desvenlafaxine—Shock—Capecitabine—prostate cancer	9.73e-05	0.000406	CcSEcCtD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	9.7e-05	0.00189	CbGpPWpGaD
Desvenlafaxine—Nervous system disorder—Capecitabine—prostate cancer	9.7e-05	0.000405	CcSEcCtD
Desvenlafaxine—Vertigo—Prednisone—prostate cancer	9.7e-05	0.000405	CcSEcCtD
Desvenlafaxine—Syncope—Prednisone—prostate cancer	9.68e-05	0.000404	CcSEcCtD
Desvenlafaxine—Tachycardia—Capecitabine—prostate cancer	9.65e-05	0.000403	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	9.65e-05	0.00187	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	9.65e-05	0.00187	CbGpPWpGaD
Desvenlafaxine—Skin disorder—Capecitabine—prostate cancer	9.61e-05	0.000401	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—TYMS—prostate cancer	9.61e-05	0.00187	CbGpPWpGaD
Desvenlafaxine—Urinary tract disorder—Epirubicin—prostate cancer	9.58e-05	0.0004	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Capecitabine—prostate cancer	9.56e-05	0.000399	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Epirubicin—prostate cancer	9.53e-05	0.000398	CcSEcCtD
Desvenlafaxine—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	9.51e-05	0.00185	CbGpPWpGaD
Desvenlafaxine—Urethral disorder—Epirubicin—prostate cancer	9.51e-05	0.000397	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Prednisone—prostate cancer	9.49e-05	0.000396	CcSEcCtD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	9.46e-05	0.00184	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	9.46e-05	0.00184	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	9.44e-05	0.00183	CbGpPWpGaD
Desvenlafaxine—Epistaxis—Doxorubicin—prostate cancer	9.43e-05	0.000393	CcSEcCtD
Desvenlafaxine—Nausea—Estradiol—prostate cancer	9.42e-05	0.000393	CcSEcCtD
Desvenlafaxine—Vomiting—Mitoxantrone—prostate cancer	9.39e-05	0.000392	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	9.37e-05	0.00182	CbGpPWpGaD
Desvenlafaxine—Convulsion—Prednisone—prostate cancer	9.35e-05	0.00039	CcSEcCtD
Desvenlafaxine—Hypertension—Prednisone—prostate cancer	9.32e-05	0.000389	CcSEcCtD
Desvenlafaxine—Rash—Mitoxantrone—prostate cancer	9.32e-05	0.000389	CcSEcCtD
Desvenlafaxine—Dermatitis—Mitoxantrone—prostate cancer	9.31e-05	0.000388	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	9.27e-05	0.0018	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—NAT1—prostate cancer	9.27e-05	0.0018	CbGpPWpGaD
Desvenlafaxine—Headache—Mitoxantrone—prostate cancer	9.26e-05	0.000386	CcSEcCtD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	9.25e-05	0.0018	CbGpPWpGaD
Desvenlafaxine—Insomnia—Docetaxel—prostate cancer	9.24e-05	0.000386	CcSEcCtD
Desvenlafaxine—Paraesthesia—Docetaxel—prostate cancer	9.17e-05	0.000383	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	9.17e-05	0.00178	CbGpPWpGaD
Desvenlafaxine—Erythema multiforme—Epirubicin—prostate cancer	9.17e-05	0.000383	CcSEcCtD
Desvenlafaxine—Anxiety—Prednisone—prostate cancer	9.16e-05	0.000382	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	9.14e-05	0.00178	CbGpPWpGaD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	9.13e-05	0.000381	CcSEcCtD
Desvenlafaxine—Somnolence—Docetaxel—prostate cancer	9.08e-05	0.000379	CcSEcCtD
Desvenlafaxine—Eye disorder—Epirubicin—prostate cancer	9.06e-05	0.000378	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Etoposide—prostate cancer	9.06e-05	0.000378	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	9.04e-05	0.00176	CbGpPWpGaD
Desvenlafaxine—Tinnitus—Epirubicin—prostate cancer	9.04e-05	0.000377	CcSEcCtD
Desvenlafaxine—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	9.01e-05	0.00175	CbGpPWpGaD
Desvenlafaxine—Cardiac disorder—Epirubicin—prostate cancer	9e-05	0.000376	CcSEcCtD
Desvenlafaxine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	8.98e-05	0.00174	CbGpPWpGaD
Desvenlafaxine—Insomnia—Capecitabine—prostate cancer	8.94e-05	0.000373	CcSEcCtD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	8.92e-05	0.00173	CbGpPWpGaD
Desvenlafaxine—Paraesthesia—Capecitabine—prostate cancer	8.88e-05	0.000371	CcSEcCtD
Desvenlafaxine—Decreased appetite—Docetaxel—prostate cancer	8.88e-05	0.000371	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Doxorubicin—prostate cancer	8.86e-05	0.00037	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Docetaxel—prostate cancer	8.82e-05	0.000368	CcSEcCtD
Desvenlafaxine—Asthenia—Etoposide—prostate cancer	8.82e-05	0.000368	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Doxorubicin—prostate cancer	8.82e-05	0.000368	CcSEcCtD
Desvenlafaxine—Fatigue—Docetaxel—prostate cancer	8.81e-05	0.000367	CcSEcCtD
Desvenlafaxine—Angiopathy—Epirubicin—prostate cancer	8.8e-05	0.000367	CcSEcCtD
Desvenlafaxine—Urethral disorder—Doxorubicin—prostate cancer	8.8e-05	0.000367	CcSEcCtD
Desvenlafaxine—Nausea—Mitoxantrone—prostate cancer	8.78e-05	0.000366	CcSEcCtD
Desvenlafaxine—Immune system disorder—Epirubicin—prostate cancer	8.76e-05	0.000366	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Epirubicin—prostate cancer	8.74e-05	0.000365	CcSEcCtD
Desvenlafaxine—Constipation—Docetaxel—prostate cancer	8.73e-05	0.000365	CcSEcCtD
Desvenlafaxine—Chills—Epirubicin—prostate cancer	8.7e-05	0.000363	CcSEcCtD
Desvenlafaxine—Shock—Prednisone—prostate cancer	8.67e-05	0.000362	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	8.66e-05	0.00168	CbGpPWpGaD
Desvenlafaxine—Nervous system disorder—Prednisone—prostate cancer	8.64e-05	0.00036	CcSEcCtD
Desvenlafaxine—Tachycardia—Prednisone—prostate cancer	8.6e-05	0.000359	CcSEcCtD
Desvenlafaxine—Decreased appetite—Capecitabine—prostate cancer	8.6e-05	0.000359	CcSEcCtD
Desvenlafaxine—Alopecia—Epirubicin—prostate cancer	8.57e-05	0.000358	CcSEcCtD
Desvenlafaxine—Skin disorder—Prednisone—prostate cancer	8.56e-05	0.000357	CcSEcCtD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	8.55e-05	0.00166	CbGpPWpGaD
Desvenlafaxine—Gastrointestinal disorder—Capecitabine—prostate cancer	8.54e-05	0.000356	CcSEcCtD
Desvenlafaxine—Fatigue—Capecitabine—prostate cancer	8.53e-05	0.000356	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Prednisone—prostate cancer	8.52e-05	0.000355	CcSEcCtD
Desvenlafaxine—Mental disorder—Epirubicin—prostate cancer	8.5e-05	0.000355	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Doxorubicin—prostate cancer	8.48e-05	0.000354	CcSEcCtD
Desvenlafaxine—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	8.48e-05	0.00165	CbGpPWpGaD
Desvenlafaxine—Constipation—Capecitabine—prostate cancer	8.46e-05	0.000353	CcSEcCtD
Desvenlafaxine—Malnutrition—Epirubicin—prostate cancer	8.44e-05	0.000352	CcSEcCtD
Desvenlafaxine—Diarrhoea—Etoposide—prostate cancer	8.41e-05	0.000351	CcSEcCtD
Desvenlafaxine—Eye disorder—Doxorubicin—prostate cancer	8.39e-05	0.00035	CcSEcCtD
Desvenlafaxine—Tinnitus—Doxorubicin—prostate cancer	8.37e-05	0.000349	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Doxorubicin—prostate cancer	8.33e-05	0.000348	CcSEcCtD
Desvenlafaxine—Tension—Epirubicin—prostate cancer	8.28e-05	0.000346	CcSEcCtD
Desvenlafaxine—Dysgeusia—Epirubicin—prostate cancer	8.27e-05	0.000345	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	8.25e-05	0.0016	CbGpPWpGaD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—PPARA—prostate cancer	8.23e-05	0.0016	CbGpPWpGaD
Desvenlafaxine—Nervousness—Epirubicin—prostate cancer	8.2e-05	0.000342	CcSEcCtD
Desvenlafaxine—Angiopathy—Doxorubicin—prostate cancer	8.14e-05	0.00034	CcSEcCtD
Desvenlafaxine—Dizziness—Etoposide—prostate cancer	8.13e-05	0.000339	CcSEcCtD
Desvenlafaxine—Immune system disorder—Doxorubicin—prostate cancer	8.1e-05	0.000338	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Doxorubicin—prostate cancer	8.09e-05	0.000337	CcSEcCtD
Desvenlafaxine—Chills—Doxorubicin—prostate cancer	8.05e-05	0.000336	CcSEcCtD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—CREBBP—prostate cancer	8.01e-05	0.00156	CbGpPWpGaD
Desvenlafaxine—Insomnia—Prednisone—prostate cancer	7.97e-05	0.000332	CcSEcCtD
Desvenlafaxine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	7.96e-05	0.00155	CbGpPWpGaD
Desvenlafaxine—Vision blurred—Epirubicin—prostate cancer	7.96e-05	0.000332	CcSEcCtD
Desvenlafaxine—Alopecia—Doxorubicin—prostate cancer	7.93e-05	0.000331	CcSEcCtD
Desvenlafaxine—Paraesthesia—Prednisone—prostate cancer	7.91e-05	0.00033	CcSEcCtD
Desvenlafaxine—Mental disorder—Doxorubicin—prostate cancer	7.86e-05	0.000328	CcSEcCtD
Desvenlafaxine—Vomiting—Etoposide—prostate cancer	7.81e-05	0.000326	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—LEP—prostate cancer	7.81e-05	0.00152	CbGpPWpGaD
Desvenlafaxine—Malnutrition—Doxorubicin—prostate cancer	7.81e-05	0.000326	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	7.78e-05	0.00151	CbGpPWpGaD
Desvenlafaxine—Rash—Etoposide—prostate cancer	7.75e-05	0.000323	CcSEcCtD
Desvenlafaxine—Dermatitis—Etoposide—prostate cancer	7.74e-05	0.000323	CcSEcCtD
Desvenlafaxine—Headache—Etoposide—prostate cancer	7.7e-05	0.000321	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	7.69e-05	0.00149	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	7.67e-05	0.00149	CbGpPWpGaD
Desvenlafaxine—Tension—Doxorubicin—prostate cancer	7.66e-05	0.00032	CcSEcCtD
Desvenlafaxine—Decreased appetite—Prednisone—prostate cancer	7.66e-05	0.00032	CcSEcCtD
Desvenlafaxine—Dysgeusia—Doxorubicin—prostate cancer	7.65e-05	0.000319	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	7.6e-05	0.00148	CbGpPWpGaD
Desvenlafaxine—Fatigue—Prednisone—prostate cancer	7.59e-05	0.000317	CcSEcCtD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	7.59e-05	0.00147	CbGpPWpGaD
Desvenlafaxine—Nervousness—Doxorubicin—prostate cancer	7.59e-05	0.000317	CcSEcCtD
Desvenlafaxine—Vertigo—Epirubicin—prostate cancer	7.58e-05	0.000316	CcSEcCtD
Desvenlafaxine—Syncope—Epirubicin—prostate cancer	7.57e-05	0.000316	CcSEcCtD
Desvenlafaxine—Constipation—Prednisone—prostate cancer	7.53e-05	0.000314	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Docetaxel—prostate cancer	7.53e-05	0.000314	CcSEcCtD
Desvenlafaxine—Palpitations—Epirubicin—prostate cancer	7.46e-05	0.000311	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Epirubicin—prostate cancer	7.42e-05	0.00031	CcSEcCtD
Desvenlafaxine—Vision blurred—Doxorubicin—prostate cancer	7.36e-05	0.000307	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	7.33e-05	0.00142	CbGpPWpGaD
Desvenlafaxine—Asthenia—Docetaxel—prostate cancer	7.33e-05	0.000306	CcSEcCtD
Desvenlafaxine—Convulsion—Epirubicin—prostate cancer	7.31e-05	0.000305	CcSEcCtD
Desvenlafaxine—Nausea—Etoposide—prostate cancer	7.3e-05	0.000305	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	7.29e-05	0.00142	CbGpPWpGaD
Desvenlafaxine—Hypertension—Epirubicin—prostate cancer	7.29e-05	0.000304	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Capecitabine—prostate cancer	7.29e-05	0.000304	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	7.21e-05	0.0014	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	7.19e-05	0.0014	CbGpPWpGaD
Desvenlafaxine—Anxiety—Epirubicin—prostate cancer	7.16e-05	0.000299	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.14e-05	0.000298	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	7.11e-05	0.00138	CbGpPWpGaD
Desvenlafaxine—Asthenia—Capecitabine—prostate cancer	7.1e-05	0.000296	CcSEcCtD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	7.08e-05	0.00138	CbGpPWpGaD
Desvenlafaxine—Dry mouth—Epirubicin—prostate cancer	7.03e-05	0.000293	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	7.03e-05	0.00137	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	7.02e-05	0.00136	CbGpPWpGaD
Desvenlafaxine—Vertigo—Doxorubicin—prostate cancer	7.02e-05	0.000293	CcSEcCtD
Desvenlafaxine—Syncope—Doxorubicin—prostate cancer	7e-05	0.000292	CcSEcCtD
Desvenlafaxine—Diarrhoea—Docetaxel—prostate cancer	6.99e-05	0.000292	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	6.95e-05	0.00135	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	6.93e-05	0.00135	CbGpPWpGaD
Desvenlafaxine—Palpitations—Doxorubicin—prostate cancer	6.9e-05	0.000288	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Doxorubicin—prostate cancer	6.87e-05	0.000286	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	6.85e-05	0.00133	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	6.83e-05	0.00133	CbGpPWpGaD
Desvenlafaxine—Shock—Epirubicin—prostate cancer	6.78e-05	0.000283	CcSEcCtD
Desvenlafaxine—Convulsion—Doxorubicin—prostate cancer	6.77e-05	0.000282	CcSEcCtD
Desvenlafaxine—Diarrhoea—Capecitabine—prostate cancer	6.77e-05	0.000282	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—GSK3B—prostate cancer	6.77e-05	0.00131	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	6.76e-05	0.00131	CbGpPWpGaD
Desvenlafaxine—Nervous system disorder—Epirubicin—prostate cancer	6.76e-05	0.000282	CcSEcCtD
Desvenlafaxine—Dizziness—Docetaxel—prostate cancer	6.75e-05	0.000282	CcSEcCtD
Desvenlafaxine—Hypertension—Doxorubicin—prostate cancer	6.74e-05	0.000281	CcSEcCtD
Desvenlafaxine—Tachycardia—Epirubicin—prostate cancer	6.72e-05	0.000281	CcSEcCtD
Desvenlafaxine—Skin disorder—Epirubicin—prostate cancer	6.69e-05	0.000279	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	6.69e-05	0.0013	CbGpPWpGaD
Desvenlafaxine—Hyperhidrosis—Epirubicin—prostate cancer	6.66e-05	0.000278	CcSEcCtD
Desvenlafaxine—Anxiety—Doxorubicin—prostate cancer	6.63e-05	0.000277	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	6.61e-05	0.00129	CbGpPWpGaD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.6e-05	0.000276	CcSEcCtD
Desvenlafaxine—Dizziness—Capecitabine—prostate cancer	6.54e-05	0.000273	CcSEcCtD
Desvenlafaxine—Dry mouth—Doxorubicin—prostate cancer	6.5e-05	0.000271	CcSEcCtD
Desvenlafaxine—Vomiting—Docetaxel—prostate cancer	6.49e-05	0.000271	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Prednisone—prostate cancer	6.49e-05	0.000271	CcSEcCtD
Desvenlafaxine—Rash—Docetaxel—prostate cancer	6.44e-05	0.000269	CcSEcCtD
Desvenlafaxine—Dermatitis—Docetaxel—prostate cancer	6.43e-05	0.000269	CcSEcCtD
Desvenlafaxine—Headache—Docetaxel—prostate cancer	6.4e-05	0.000267	CcSEcCtD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—prostate cancer	6.36e-05	0.00124	CbGpPWpGaD
Desvenlafaxine—Asthenia—Prednisone—prostate cancer	6.32e-05	0.000264	CcSEcCtD
Desvenlafaxine—Vomiting—Capecitabine—prostate cancer	6.29e-05	0.000262	CcSEcCtD
Desvenlafaxine—Shock—Doxorubicin—prostate cancer	6.27e-05	0.000262	CcSEcCtD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	6.25e-05	0.00122	CbGpPWpGaD
Desvenlafaxine—Nervous system disorder—Doxorubicin—prostate cancer	6.25e-05	0.000261	CcSEcCtD
Desvenlafaxine—Rash—Capecitabine—prostate cancer	6.24e-05	0.00026	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	6.23e-05	0.00121	CbGpPWpGaD
Desvenlafaxine—Insomnia—Epirubicin—prostate cancer	6.23e-05	0.00026	CcSEcCtD
Desvenlafaxine—Dermatitis—Capecitabine—prostate cancer	6.23e-05	0.00026	CcSEcCtD
Desvenlafaxine—Tachycardia—Doxorubicin—prostate cancer	6.22e-05	0.00026	CcSEcCtD
Desvenlafaxine—Headache—Capecitabine—prostate cancer	6.2e-05	0.000259	CcSEcCtD
Desvenlafaxine—Skin disorder—Doxorubicin—prostate cancer	6.19e-05	0.000258	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	6.19e-05	0.0012	CbGpPWpGaD
Desvenlafaxine—Paraesthesia—Epirubicin—prostate cancer	6.19e-05	0.000258	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Doxorubicin—prostate cancer	6.16e-05	0.000257	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—SERPINE1—prostate cancer	6.13e-05	0.00119	CbGpPWpGaD
Desvenlafaxine—Somnolence—Epirubicin—prostate cancer	6.12e-05	0.000256	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	6.1e-05	0.00119	CbGpPWpGaD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—CASP3—prostate cancer	6.09e-05	0.00118	CbGpPWpGaD
Desvenlafaxine—Nausea—Docetaxel—prostate cancer	6.07e-05	0.000253	CcSEcCtD
Desvenlafaxine—Diarrhoea—Prednisone—prostate cancer	6.03e-05	0.000252	CcSEcCtD
Desvenlafaxine—Decreased appetite—Epirubicin—prostate cancer	5.99e-05	0.00025	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTA3—prostate cancer	5.97e-05	0.00116	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—GNG5—prostate cancer	5.95e-05	0.00116	CbGpPWpGaD
Desvenlafaxine—Gastrointestinal disorder—Epirubicin—prostate cancer	5.95e-05	0.000248	CcSEcCtD
Desvenlafaxine—Fatigue—Epirubicin—prostate cancer	5.94e-05	0.000248	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	5.91e-05	0.00115	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	5.89e-05	0.00115	CbGpPWpGaD
Desvenlafaxine—Constipation—Epirubicin—prostate cancer	5.89e-05	0.000246	CcSEcCtD
Desvenlafaxine—Nausea—Capecitabine—prostate cancer	5.87e-05	0.000245	CcSEcCtD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	5.87e-05	0.00114	CbGpPWpGaD
Desvenlafaxine—Dizziness—Prednisone—prostate cancer	5.83e-05	0.000243	CcSEcCtD
Desvenlafaxine—Insomnia—Doxorubicin—prostate cancer	5.77e-05	0.000241	CcSEcCtD
Desvenlafaxine—Paraesthesia—Doxorubicin—prostate cancer	5.72e-05	0.000239	CcSEcCtD
Desvenlafaxine—Somnolence—Doxorubicin—prostate cancer	5.67e-05	0.000236	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	5.64e-05	0.0011	CbGpPWpGaD
Desvenlafaxine—Vomiting—Prednisone—prostate cancer	5.6e-05	0.000234	CcSEcCtD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.56e-05	0.00108	CbGpPWpGaD
Desvenlafaxine—Rash—Prednisone—prostate cancer	5.55e-05	0.000232	CcSEcCtD
Desvenlafaxine—Dermatitis—Prednisone—prostate cancer	5.55e-05	0.000232	CcSEcCtD
Desvenlafaxine—Decreased appetite—Doxorubicin—prostate cancer	5.54e-05	0.000231	CcSEcCtD
Desvenlafaxine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.52e-05	0.00107	CbGpPWpGaD
Desvenlafaxine—Headache—Prednisone—prostate cancer	5.52e-05	0.00023	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.5e-05	0.00023	CcSEcCtD
Desvenlafaxine—Fatigue—Doxorubicin—prostate cancer	5.5e-05	0.000229	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.46e-05	0.00106	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.46e-05	0.00106	CbGpPWpGaD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—EP300—prostate cancer	5.45e-05	0.00106	CbGpPWpGaD
Desvenlafaxine—Constipation—Doxorubicin—prostate cancer	5.45e-05	0.000227	CcSEcCtD
Desvenlafaxine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.45e-05	0.00106	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.39e-05	0.00105	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.36e-05	0.00104	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.33e-05	0.00103	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.26e-05	0.00102	CbGpPWpGaD
Desvenlafaxine—Nausea—Prednisone—prostate cancer	5.23e-05	0.000218	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.19e-05	0.00101	CbGpPWpGaD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—prostate cancer	5.16e-05	0.001	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTA1—prostate cancer	5.14e-05	0.000998	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTO1—prostate cancer	5.08e-05	0.000987	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—NAT2—prostate cancer	5.08e-05	0.000987	CbGpPWpGaD
Desvenlafaxine—Hypersensitivity—Epirubicin—prostate cancer	5.08e-05	0.000212	CcSEcCtD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	5.07e-05	0.000985	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	5.01e-05	0.000974	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	5.01e-05	0.000974	CbGpPWpGaD
Desvenlafaxine—SLC6A4—NRF2 pathway—TGFB1—prostate cancer	5e-05	0.000971	CbGpPWpGaD
Desvenlafaxine—Asthenia—Epirubicin—prostate cancer	4.94e-05	0.000206	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	4.87e-05	0.000947	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	4.8e-05	0.000934	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	4.78e-05	0.000929	CbGpPWpGaD
Desvenlafaxine—Diarrhoea—Epirubicin—prostate cancer	4.71e-05	0.000197	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Doxorubicin—prostate cancer	4.7e-05	0.000196	CcSEcCtD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—PTEN—prostate cancer	4.67e-05	0.000907	CbGpPWpGaD
Desvenlafaxine—Asthenia—Doxorubicin—prostate cancer	4.57e-05	0.000191	CcSEcCtD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	4.56e-05	0.000887	CbGpPWpGaD
Desvenlafaxine—Dizziness—Epirubicin—prostate cancer	4.56e-05	0.00019	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.53e-05	0.00088	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.48e-05	0.00087	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.47e-05	0.000868	CbGpPWpGaD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—EP300—prostate cancer	4.45e-05	0.000865	CbGpPWpGaD
Desvenlafaxine—Vomiting—Epirubicin—prostate cancer	4.38e-05	0.000183	CcSEcCtD
Desvenlafaxine—Diarrhoea—Doxorubicin—prostate cancer	4.36e-05	0.000182	CcSEcCtD
Desvenlafaxine—Rash—Epirubicin—prostate cancer	4.34e-05	0.000181	CcSEcCtD
Desvenlafaxine—Dermatitis—Epirubicin—prostate cancer	4.34e-05	0.000181	CcSEcCtD
Desvenlafaxine—Headache—Epirubicin—prostate cancer	4.32e-05	0.00018	CcSEcCtD
Desvenlafaxine—SLC6A2—NRF2 pathway—TGFB1—prostate cancer	4.3e-05	0.000835	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.26e-05	0.000828	CbGpPWpGaD
Desvenlafaxine—Dizziness—Doxorubicin—prostate cancer	4.22e-05	0.000176	CcSEcCtD
Desvenlafaxine—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.21e-05	0.000819	CbGpPWpGaD
Desvenlafaxine—Nausea—Epirubicin—prostate cancer	4.09e-05	0.000171	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—HPGDS—prostate cancer	4.06e-05	0.000789	CbGpPWpGaD
Desvenlafaxine—Vomiting—Doxorubicin—prostate cancer	4.05e-05	0.000169	CcSEcCtD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	4.04e-05	0.000784	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.03e-05	0.000783	CbGpPWpGaD
Desvenlafaxine—Rash—Doxorubicin—prostate cancer	4.02e-05	0.000168	CcSEcCtD
Desvenlafaxine—Dermatitis—Doxorubicin—prostate cancer	4.02e-05	0.000168	CcSEcCtD
Desvenlafaxine—Headache—Doxorubicin—prostate cancer	3.99e-05	0.000167	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	3.98e-05	0.000774	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTT1—prostate cancer	3.94e-05	0.000766	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	3.89e-05	0.000757	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—RXRA—prostate cancer	3.83e-05	0.000745	CbGpPWpGaD
Desvenlafaxine—Nausea—Doxorubicin—prostate cancer	3.79e-05	0.000158	CcSEcCtD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.74e-05	0.000726	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.73e-05	0.000725	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.68e-05	0.000715	CbGpPWpGaD
Desvenlafaxine—SLC6A4—SIDS Susceptibility Pathways—IL6—prostate cancer	3.57e-05	0.000694	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.55e-05	0.00069	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.31e-05	0.000643	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.27e-05	0.000635	CbGpPWpGaD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—TP53—prostate cancer	3.19e-05	0.000619	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.14e-05	0.00061	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.1e-05	0.000602	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.04e-05	0.000591	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2.99e-05	0.000582	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.95e-05	0.000573	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—PPARA—prostate cancer	2.93e-05	0.000569	CbGpPWpGaD
Desvenlafaxine—SLC6A4—Circadian rythm related genes—IL6—prostate cancer	2.92e-05	0.000567	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.91e-05	0.000566	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.85e-05	0.000553	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—COMT—prostate cancer	2.74e-05	0.000533	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.73e-05	0.000531	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.71e-05	0.000526	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.69e-05	0.000523	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.51e-05	0.000488	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.47e-05	0.000481	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.38e-05	0.000462	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—HAO1—prostate cancer	2.35e-05	0.000456	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.35e-05	0.000456	CbGpPWpGaD
Desvenlafaxine—SLC6A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.32e-05	0.000452	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—ADI1—prostate cancer	1.91e-05	0.000372	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PSAT1—prostate cancer	1.91e-05	0.000372	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—TST—prostate cancer	1.91e-05	0.000372	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CSAD—prostate cancer	1.91e-05	0.000372	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GRHL1—prostate cancer	1.91e-05	0.000372	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CBR1—prostate cancer	1.91e-05	0.000372	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CKMT2—prostate cancer	1.78e-05	0.000346	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.78e-05	0.000346	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GRHPR—prostate cancer	1.78e-05	0.000346	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.78e-05	0.000346	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTM3—prostate cancer	1.67e-05	0.000325	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.67e-05	0.000325	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—RFK—prostate cancer	1.67e-05	0.000325	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—AOX1—prostate cancer	1.67e-05	0.000325	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NAGLU—prostate cancer	1.67e-05	0.000325	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.67e-05	0.000325	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PGAM2—prostate cancer	1.67e-05	0.000325	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.59e-05	0.000308	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—AMACR—prostate cancer	1.59e-05	0.000308	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—DEGS1—prostate cancer	1.59e-05	0.000308	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NAT1—prostate cancer	1.59e-05	0.000308	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.59e-05	0.000308	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.51e-05	0.000294	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.35e-05	0.000262	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—HPGD—prostate cancer	1.35e-05	0.000262	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.27e-05	0.000246	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.23e-05	0.00024	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—MTAP—prostate cancer	1.23e-05	0.00024	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.2e-05	0.000234	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.2e-05	0.000234	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—ACSL4—prostate cancer	1.15e-05	0.000223	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.15e-05	0.000223	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—UMPS—prostate cancer	1.1e-05	0.000214	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PHGDH—prostate cancer	1.1e-05	0.000214	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—ARG2—prostate cancer	1.1e-05	0.000214	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—LDHB—prostate cancer	1.08e-05	0.000209	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.06e-05	0.000206	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PDHA1—prostate cancer	1.02e-05	0.000199	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—TCN2—prostate cancer	1.02e-05	0.000199	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—UCP3—prostate cancer	1.02e-05	0.000199	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTA3—prostate cancer	1.02e-05	0.000199	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—HSD3B1—prostate cancer	9.75e-06	0.000189	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SLC22A3—prostate cancer	9.75e-06	0.000189	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.35e-06	0.000182	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTA4—prostate cancer	9.35e-06	0.000182	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTA2—prostate cancer	9.11e-06	0.000177	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SULT1A1—prostate cancer	9e-06	0.000175	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—ABCG5—prostate cancer	9e-06	0.000175	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTA1—prostate cancer	8.79e-06	0.000171	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—HSD3B2—prostate cancer	8.69e-06	0.000169	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTO1—prostate cancer	8.69e-06	0.000169	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NAT2—prostate cancer	8.69e-06	0.000169	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PLCB2—prostate cancer	8.33e-06	0.000162	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—LRP2—prostate cancer	8.33e-06	0.000162	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.33e-06	0.000162	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—P4HB—prostate cancer	8.17e-06	0.000159	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.95e-06	0.000154	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.74e-06	0.00015	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—MED12—prostate cancer	7.62e-06	0.000148	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GNG5—prostate cancer	7.56e-06	0.000147	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NCOA3—prostate cancer	7.28e-06	0.000141	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—HPGDS—prostate cancer	6.95e-06	0.000135	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.9e-06	0.000134	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—ACHE—prostate cancer	6.74e-06	0.000131	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTT1—prostate cancer	6.74e-06	0.000131	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.66e-06	0.000129	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.48e-06	0.000126	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PRKACB—prostate cancer	6.44e-06	0.000125	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.38e-06	0.000124	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NCOA2—prostate cancer	6.08e-06	0.000118	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.8e-06	0.000113	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.66e-06	0.00011	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NQO1—prostate cancer	5.6e-06	0.000109	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—TH—prostate cancer	5.52e-06	0.000107	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.37e-06	0.000104	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GGT1—prostate cancer	5.2e-06	0.000101	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NCOA1—prostate cancer	5.12e-06	9.95e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.05e-06	9.81e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—RXRA—prostate cancer	4.87e-06	9.46e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—COMT—prostate cancer	4.69e-06	9.12e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTP1—prostate cancer	4.67e-06	9.07e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—ITPR1—prostate cancer	4.59e-06	8.93e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—TYMS—prostate cancer	4.34e-06	8.44e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—GSTM1—prostate cancer	4.29e-06	8.34e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—LPL—prostate cancer	4.21e-06	8.18e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.07e-06	7.9e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—ERCC2—prostate cancer	4.03e-06	7.84e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—MTHFR—prostate cancer	3.79e-06	7.37e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PPARA—prostate cancer	3.72e-06	7.23e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CAV1—prostate cancer	3.5e-06	6.8e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.19e-06	6.19e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—INS—prostate cancer	3.02e-06	5.86e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—CREBBP—prostate cancer	2.95e-06	5.74e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.8e-06	5.44e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—NOS3—prostate cancer	2.64e-06	5.14e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.44e-06	4.74e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PTGS2—prostate cancer	2.42e-06	4.7e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PTEN—prostate cancer	2.11e-06	4.1e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—EP300—prostate cancer	2.01e-06	3.91e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.49e-06	2.89e-05	CbGpPWpGaD
Desvenlafaxine—CYP3A4—Metabolism—AKT1—prostate cancer	1.22e-06	2.36e-05	CbGpPWpGaD
